Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 2 of 350 for:    Emphysema

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

This study has been completed.
Boehringer Ingelheim
Information provided by:
Gelb, Arthur F., M.D. Identifier:
First received: December 10, 2007
Last updated: August 13, 2008
Last verified: December 2007

To evaluate if tiotropium (Spiriva)induced bronchodilation of inspiratory capacity in patients with moderate to severe copd subjected to metronome paced hyperventilation induced dynamic hyperinflation is dependent upon the extent of underlying emphysema as determined by high resolution-thin section CT lung.

Condition Intervention Phase
Drug: tiotropium
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Retrospective
Official Title: Effectiveness of Tiotropium to Maintain Inspiratory Capacity Against Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in COPD Patients With Lung CT Scored Emphysema

Resource links provided by NLM:

Further study details as provided by Gelb, Arthur F., M.D.:

Primary Outcome Measures:
  • Correlate tiotropium induced increase in inspiratory capacity (IC)and FEV 1 with extent of emphysema as scored by lung CT. [ Time Frame: After 30 days and 1.5hr of tiotropium ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Correlate decrease in IC and FEV 1 following dynamic hyperinflation with underlying emphysema. [ Time Frame: After 30 days and 1.5hr of tiotropium ] [ Designated as safety issue: No ]

Enrollment: 29
Study Start Date: August 2004
Study Completion Date: August 2005
Groups/Cohorts Assigned Interventions
patients with moderate to severe copd with varying extent of emphysema
Drug: tiotropium
18ug capsule daily for 30 days
Other Name: Spiriva

Detailed Description:

We will analyze post hoc, data that was previously published: Gelb AF et al.Chest 2006;131:690-695. We have shown that tiotropium increases resting inspiratory capacity thereby providing lung volume protection against metronome paced hyperventilation induced dynamic hyperinflation. End point will be to correlate increase in tiotropium induced FEV 1(L) and inspiratory capacity with extent of underlying emphysema as scored by lung CT ( Gelb AF et al:Chest 1996; 109: 353-359)in 29 patients with COPD. We will also correlate the decrease in inspiratory capacity following metronome paced hyperventilation induced dynamic hyperinflation with extent of lung CT scored emphysema.


Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with moderate to severe copd from tertiary care pulmonary clinic


Inclusion Criteria

  • moderate to severe copd

Exclusion Criteria

  • unable to tolerate tiotropium
  • unable to perform metronome paced hyperventilation induced dynamic hyperinflation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00570544

United States, California
Arthur F Gelb Medical Corporation
Lakewood, California, United States, 90712
Sponsors and Collaborators
Gelb, Arthur F., M.D.
Boehringer Ingelheim
Principal Investigator: Arthur F Gelb, MD Arthur F Gelb Medical Corporation
  More Information

Responsible Party: Arthur F Gelb MD, Arthur F Gelb Medical Corporation Identifier: NCT00570544     History of Changes
Other Study ID Numbers: 1000, Boehringer-Ingelheim Pharm., Pfizer
Study First Received: December 10, 2007
Last Updated: August 13, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Gelb, Arthur F., M.D.:
lung function
dynamic hyperinflation

Additional relevant MeSH terms:
Pulmonary Emphysema
Lung Diseases
Lung Diseases, Obstructive
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on February 27, 2015